Joseph Tillotson

机构：Center for Drug Evaluation and Research, Pfizer (United States), PRX Research · ORCID：0000-0003-0795-5494

发表论文 41 篇 · 总被引 545 次 · h-index 14

代表论文

• Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model (2024 · Science Advances · 被引 55)
• Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity (2018 · Clinical Cancer Research · 被引 45)
• Non-covalent NRF2 Activation Confers Greater Cellular Protection than Covalent Activation (2019 · Cell chemical biology · 被引 42)
• ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A (2017 · Bioorganic & Medicinal Chemistry Letters · 被引 33)
• Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067 (2018 · PLoS ONE · 被引 18)
• Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells (2018 · AIDS Research and Human Retroviruses · 被引 18)